PharmAla secures MDMA patent and hires Canaccord as banking partner
PharmAla Biotech Holdings has delivered a three-part corporate update that strengthens its intellectual property position, reclaims a drug candidate from a dissolved licensing structure, and brings in a heavyweight capital markets adviser as the Toronto-listed company positions itself for what it believes is an improving regulatory environment for MDXX-class therapeutics.
The company (CSE: MDMA; OTCQB: MDXXF) announced on 21 August 2026 that the US Patent and Trademark Office has granted US Patent No. 12,679,817, covering novel enantioselective processes for preparing the (R)- and (S)-enantiomers of MDMA and of MBDB, a structurally related compound.
Manufacturing edge
MDMA is a chiral molecule: its two mirror-image forms, or enantiomers, have distinct pharmacological profiles, but conventional synthesis yields a racemic 50:50 mixture. Separating enantiomers at commercial scale has historically been expensive and low-yielding. PharmAla says its patented processes prepare individual enantiomers directly, which it believes will underpin the economical manufacture of R-MDMA and of its own lead candidate, ALA-002, a patented non-racemic MDMA formulation that holds New Chemical Entity designation from the FDA.
Founding chief executive Nicholas Kadysh framed the patent as addressing a gap that competitors have largely ignored. "Everyone in this sector talks about molecules," he said. "Far fewer talk about how you actually make them at scale, at cost, and to GMP standard, and that is usually what decides whether a drug is commercially viable."
The grant adds a manufacturing-process layer to PharmAla's existing composition-of-matter and formulation IP, creating a potentially defensible position for a company that describes itself as the only entity currently supplying clinical-grade MDMA for patient treatments outside clinical trials.
APA-01 strategy reset and banking mandate
PharmAla has also exercised its contractual option to cancel the proposed licensing of APA-01, its second MDXX candidate, to Restora Neurosciences, a special purpose vehicle formed jointly with Aluvaris and Diteba in May 2026. The company cited two developments that shifted the calculus. First, a July 2026 licensing deal with NASDAQ-listed Jupiter Neurosciences, granting Jupiter exclusive US rights to ALA-002, demonstrated that PharmAla can monetise assets directly and on what it characterises as attractive terms. Second, it has been publicly reported that Resilient Pharmaceuticals, formerly known as Lykos Therapeutics and MAPS Public Benefit Corporation, has resubmitted a New Drug Application to the FDA for MDMA-assisted therapy in PTSD. PharmAla is not party to that filing and said it cannot verify its status independently.
APA-01 is under evaluation for potential use in psychological trauma, post-stroke neurorehabilitation, and traumatic brain injury. It has no active IND and has not been approved by any regulator. PharmAla said significant interest in the molecule was demonstrated during the Restora process, and it will now assess both in-house development and co-development routes.
Completing the update, PharmAla confirmed it signed a letter of engagement on 10 August 2026 appointing Canaccord Genuity LLC as exclusive financial adviser and placement agent. The mandate covers equity and debt offerings and strategic transactions including mergers, joint ventures, and asset sales. Commercial terms were not disclosed, and Canaccord has made no commitment to underwrite or place any specific security.
Market context
The MDXX therapeutic space remains nascent but has attracted sustained venture and strategic interest. The regulatory path for MDMA-assisted therapy is contested: the FDA declined to approve Lykos's original NDA in August 2024, citing concerns about trial design and data integrity, making the reported resubmission by Resilient Pharmaceuticals a closely watched event for the sector. A positive outcome would open a precedent that smaller developers such as PharmAla could reference in their own regulatory discussions. For now, PharmAla's dual identity as manufacturer and developer, backed by a growing patent estate and a named banking partner, leaves it reasonably well positioned to pursue either a partnering or a capital-raise path through 2027.